Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-009575
Filing Date
2025-05-12
Accepted
2025-05-12 08:30:39
Documents
59
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1139404
2 EX-31.1 ex31-1.htm EX-31.1 14651
3 EX-31.2 ex31-2.htm EX-31.2 14771
4 EX-32.1 ex32-1.htm EX-32.1 5419
5 EX-32.2 ex32-2.htm EX-32.2 5494
  Complete submission text file 0001641172-25-009575.txt   6343775

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE lixt-20250331.xsd EX-101.SCH 47609
7 XBRL CALCULATION FILE lixt-20250331_cal.xml EX-101.CAL 32684
8 XBRL DEFINITION FILE lixt-20250331_def.xml EX-101.DEF 245256
9 XBRL LABEL FILE lixt-20250331_lab.xml EX-101.LAB 419081
10 XBRL PRESENTATION FILE lixt-20250331_pre.xml EX-101.PRE 328986
61 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 957140
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39717 | Film No.: 25932742
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)